RUN vs RXRX · P/E 6.0, rev $2.04B vs rev $58.8M
Sunrun Inc (RUN) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
RUN currently screens at market cap $3.05B and trailing P/E 6.0. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the RUN and RXRX stock pages for the full models.
Not investment advice.